Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Therapeutic nanoparticles (TNPs) aim to deliver drugs more safely and effectively to cancers, yet clinical results have been unpredictable owing to limited in vivo understanding. Here we use single-cell imaging of intratumoral TNP pharmacokinetics and pharmacodynamics to better comprehend their heterogeneous behaviour. Model TNPs comprising a fluorescent platinum(IV) pro-drug and a clinically tested polymer platform (PLGA-b-PEG) promote long drug circulation and alter accumulation by directing cellular uptake toward tumour-associated macrophages (TAMs). Simultaneous imaging of TNP vehicle, its drug payload and single-cell DNA damage response reveals that TAMs serve as a local drug depot that accumulates significant vehicle from which DNA-damaging Pt payload gradually releases to neighbouring tumour cells. Correspondingly, TAM depletion reduces intratumoral TNP accumulation and efficacy. Thus, nanotherapeutics co-opt TAMs for drug delivery, which has implications for TNP design and for selecting patients into trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Miller et al. found a reduction in liver metastases due to enhanced delivery of nano‐encapsulated platinum in the TME via TAMs in a breast cancer mouse model [87].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
A global double-fluorescent Cre reporter mouse
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. (2007) · genesis · doi:10.1002/dvg.20335 · Cited by 3,491
The Chemistry of Fluorescent Bodipy Dyes: Versatility Unsurpassed
Ulrich, G., Ziessel, R., & Harriman, A. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200702070 · Cited by 3,161
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Self-citationMacrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Cited by
Items 101–200 of 448
Guo, L., Zhang, Y., Yang, Z., Peng, H., Wei, R., Wang, C., & Feng, M. (2019) · ACS Nano · doi:10.1021/acsnano.8b08872 · Cited by 97
Li, T., Li, K., Wang, C., Liu, X. Z., Wen, Y., Xu, Y., Zhang, Q., Zhao, Q.-Y., Shao, M., Li, Y.-Z., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.024 · Cited by 98
“study demonstrating uptake of therapeutic nanoparticles by TAM in a peripheral tumor model [24].”
BackgroundImaging of anticancer drug action in single cells
Miller, M. A., & Weissleder, R. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.41 · Cited by 92
Self-citationPassive targeting in nanomedicine: fundamental concepts, body interactions, and clinical potential
Narum, S. M., Le, T., Le, D. P., Lee, J. C., Donahue, N. D., Yang, W., & Wilhelm, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816662-8.00004-7 · Cited by 108
Applying artificial intelligence and computational modeling to nanomedicine
Hamilton, S., & Kingston, B. R. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103043 · Cited by 97
Microgels in biomaterials and nanomedicines
Wang, Y., Guo, L., Dong, S., Cui, J., & Hao, J. (2019) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2019.01.005 · Cited by 93
Quantitating drug-target engagement in single cells in vitro and in vivo
Dubach, J. M., Kim, E., Yang, K., Cuccarese, M., Giedt, R. J., Meimetis, L. G., Vinegoni, C., & Weissleder, R. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2248 · Cited by 87
Self-citationWang, W., Liang, G., Zhang, W., Xing, D., & Hu, X. (2018) · Chemistry of Materials · doi:10.1021/acs.chemmater.8b01149 · Cited by 88
Bortot, B., Mangogna, A., Lorenzo, G. D., Stabile, G., Ricci, G., & Biffi, S. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01926-y · Cited by 95
“The mechanism by which NPs enter solid tumours was more complex than previously thought, and immune cells in the tumour microenvironment play critical roles in the accumulation, retention, and tumoral distribution of nanomedicines [83, 84].”
BackgroundTsvetkova, Y., Beztsinna, N., Baues, M., Klein, D., Rix, A., Golombek, S. K., Al Rawashdeh, W., Gremse, F., Barz, M., Koynov, K., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b01171 · Cited by 84
Chloroquine and nanoparticle drug delivery: A promising combination
Pelt, J., Busatto, S., Mauro Ferrari, B., Thompson, E. A., Mody, K., & Wolfram, J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.007 · Cited by 93
Raza, M. K., Gautam, S., Howlader, P., Bhattacharyya, A., Kondaiah, P., & Chakravarty, A. R. (2018) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.8b02546 · Cited by 88
Tan, T., Wang, H., Cao, H., Zeng, L., Wang, Y., Wang, Z., Wang, J., Li, J., Wang, S., Zhang, Z., et al. (2018) · Advanced Science · doi:10.1002/advs.201801012 · Cited by 83
Cao, S., Saw, P. E., Shen, Q., Li, R., Liu, Y., & Xu, X. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121264 · Cited by 84
Wang, J., Yuan, J., Chen, C., Wang, L., Zhai, Z., Fu, Q., Liu, Y., Dong, L., Yan, W., Li, A., et al. (2020) · Nano Energy · doi:10.1016/j.nanoen.2020.104914 · Cited by 82
Wang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 71
Chen, S., Ma, T., Wang, J., Liang, S., Liao, H., Tan, W., Chen, M., Zhou, X., Xu, Y., Wang, L., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2023.122456 · Cited by 85
Polysaccharide-based nanocarriers for efficient transvascular drug delivery
Zhang, M., Ma, H., Wang, X., Yu, B., Cong, H., & Shen, Y. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.051 · Cited by 77
Stapleton, S., Dunne, M., Milosevic, M., Tran, C. W., Gold, M. J., Vedadi, A., Mckee, T. D., Ohashi, P. S., Allen, C., & Jaffray, D. A. (2018) · ACS Nano · doi:10.1021/acsnano.7b06301 · Cited by 80
Atukorale, P. U., Raghunathan, S. P., Raguveer, V., Moon, T. J., Zheng, C., Bielecki, P. A., Wiese, M. L., Goldberg, A. L., Covarrubias, G., Hoimes, C. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0381 · Cited by 83
Mathematical and computational modeling of nano-engineered drug delivery systems
Shamsi, M., Mohammadi, A., Manshadi, M. K. D., & Sanati-Nezhad, A. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.014 · Cited by 79
Wayne, E. C., Long, C., Haney, M. J., Batrakova, E. V., Leisner, T. M., Parise, L. V., & Kabanov, A. V. (2019) · Advanced Science · doi:10.1002/advs.201900582 · Cited by 83
Eskandari, A., & Suntharalingam, K. (2019) · Chemical Science · doi:10.1039/c9sc01275c · Cited by 82
Semiconducting polymer dots with bright narrow-band emission at 800 nm for biological applications
Chen, D., Wu, I.-C., Liu, Z., Tang, Y., Chen, H., Yu, J., Wu, C., & Chiu, D. T. (2017) · Chemical Science · doi:10.1039/c7sc00441a · Cited by 78
Machine Learning‐Enhanced Nanoparticle Design for Precision Cancer Drug Delivery
Wang, Q., Liu, Y., Li, C., Xu, S., Xu, S., & Liu, B. (2025) · Advanced Science · doi:10.1002/advs.202503138 · Cited by 103
Fluorescence anisotropy imaging in drug discovery
Vinegoni, C., Feruglio, P. F., Gryczyński, I., Mazitschek, R., & Weissleder, R. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.019 · Cited by 82
“By extending FP/FA to optical microscopy imaging modalities, in combination with measurements of fluorescence intensity, and co-localization with fluorescent reporter proteins, we have demonstrated that one can obtain spatially and temporally resolved cellular mapping both in vivo and in vitro, enabling insights into…”
Self-citationChen, Y., Huang, Y., Zhou, S., Sun, M., Chen, L., Wang, J., Xu, M., Liu, S., Liang, K., Zhang, Q., et al. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c02622 · Cited by 78
The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy
Neophytou, C. M., Pierides, C., Christodoulou, M., Costeas, P., Kyriakou, T.-C., & Papageorgis, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00899 · Cited by 83
“The presence of TAMs can therefore affect the design and use of TNPs for tumor targeting (92).”
BackgroundBarrier permeation and improved nanomedicine delivery in tumor microenvironments
Liu, J., Zhang, J., Gao, Y., Jiang, Y., Guan, Z., Xie, Y., Hu, J., & Chen, J. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216166 · Cited by 77
Recording the wild lives of immune cells
Pittet, M. J., Garris, C., Arlauckas, S. P., & Weissleder, R. (2018) · Science Immunology · doi:10.1126/sciimmunol.aaq0491 · Cited by 77
Self-citationPrediction of anti-cancer nanotherapy efficacy by imaging
Miller, M. A., Arlauckas, S., & Weissleder, R. (2017) · Nanotheranostics · doi:10.7150/ntno.20564 · Cited by 74
Self-citationMiller, M. A., & Weissleder, R. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.023 · Cited by 73
“Cellular PD response reveals extent of TAM drug-depot effects—”
BackgroundMethodResultInfluentialSelf-citationGlucose-Appended Platinum(II)-BODIPY Conjugates for Targeted Photodynamic Therapy in Red Light
Ramu, V., Gautam, S., Garai, A., Kondaiah, P., & Chakravarty, A. R. (2018) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.7b02249 · Cited by 74
Riboflavin-Targeted Drug Delivery
Darguzyte, M., Drude, N., Lammers, T., & Kiessling, F. M. (2020) · Cancers · doi:10.3390/cancers12020295 · Cited by 83
Monocyte-mediated Chemotherapy Drug Delivery in Glioblastoma
Wang, C., Li, K., Li, T., Chen, Z., Wen, Y., Liu, X., Jia, X., Zhang, Y., Xu, Y., Han, M. H., et al. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0266 · Cited by 74
Li, J., Wang, H., Wang, Y., Gong, X., Xu, X., Sha, X., Zhang, A., Zhang, Z., & Li, Y. (2020) · Advanced Materials · doi:10.1002/adma.202002380 · Cited by 74
Pusuluri, A., Wu, D., & Mitragotri, S. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.020 · Cited by 73
Histopathological biomarkers for predicting the tumour accumulation of nanomedicines
May, J., Moss, J. I., Mueller, F., Golombek, S. K., Biancacci, I., Rizzo, L. Y., Elshafei, A. S., Gremse, F., Pola, R., Pechar, M., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01197-4 · Cited by 74
Monitoring EPR Effect Dynamics during Nanotaxane Treatment with Theranostic Polymeric Micelles
Biancacci, I., De Lorenzi, F., Theek, B., Bai, X., May, J., Consolino, L., Baues, M., Moeckel, D., Gremse, F., von Stillfried, S., et al. (2022) · Advanced Science · doi:10.1002/advs.202103745 · Cited by 68
Saborano, R., Wongpinyochit, T., Totten, J. D., Johnston, B. F., Seib, F. P., & Duarte, I. F. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201601240 · Cited by 68
Nanoscale delivery systems for cancer immunotherapy
Wang, Z., Liu, W., Shi, J., Chen, N., & Fan, C. (2018) · Materials Horizons · doi:10.1039/c7mh00991g · Cited by 69
Copper chalcogenide materials as photothermal agents for cancer treatment
Liu, K., Liu, K., Liu, J., Ren, Q., Zhao, Z., Wu, X., Li, D., Yuan, F., Ye, K., & Li, B. (2020) · Nanoscale · doi:10.1039/c9nr08737k · Cited by 67
Extravasating Neutrophils Open Vascular Barrier and Improve Liposomes Delivery to Tumors
Naumenko, V. A., Vlasova, K. Y., Garanina, A. S., Melnikov, P. A., Potashnikova, D. M., Vishnevskiy, D. A., Vodopyanov, S. S., Chekhonin, V. P., Abakumov, M. A., & Majouga, A. G. (2019) · ACS Nano · doi:10.1021/acsnano.9b03848 · Cited by 66
Chen, L., Chen, D., Jiang, Y., Zhang, J., Yu, J., DuFort, C. C., Hingorani, S. R., Zhang, X., Wu, C., & Chiu, D. T. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201902077 · Cited by 63
Translational considerations in nanomedicine: The oncology perspective
Gabizón, A., de Rosales, R. T. M., & La-Beck, N. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.012 · Cited by 64
Drozdov, A. S., Nikitin, P. I., & Rozenberg, J. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313011 · Cited by 67
“It has been noted that macrophages, being the major professional nanoparticle sequestration cells, accumulate the majority of the nanoparticles in tumors [91,142].”
BackgroundRole of Tumor-Associated Macrophages in Sarcomas
Fujiwara, T., Healey, J. H., Ogura, K., Yoshida, A., Kondo, H., Hata, T., Kure, M., Tazawa, H., Nakata, E., Kunisada, T., et al. (2021) · Cancers · doi:10.3390/cancers13051086 · Cited by 64
Improving nanotherapy delivery and action through image-guided systems pharmacology
Ng, T. S. C., Garlin, M. A., Weissleder, R., & Miller, M. A. (2020) · Theranostics · doi:10.7150/thno.37215 · Cited by 60
“Reports have implicated phagocytic TAMs [4, 25, 31] and circulating monocytes [179] as important components affecting tumor NP kinetics, and myeloid NP uptake may likewise be considered one of multiple stages in the delivery of certain TNP designs.”
BackgroundMethodResultInfluentialSelf-citationRazavi, Z. S., Alizadeh, S. S., Razavi, F. S., Souri, M., & Soltani, M. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125186 · Cited by 65
Greene, M. K., Johnston, M. C., & Scott, C. J. (2021) · Cancers · doi:10.3390/cancers13246175 · Cited by 61
Zia, Q., Owais, M., Rauf, M. A., Khan, W., & Zubair, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-11847-0 · Cited by 62
Xu, X., Gong, X., Wang, Y., Li, J., Wang, H., Wang, J., Sha, X., Li, Y., & Zhang, Z. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900181 · Cited by 60
Liu, J., Zhao, X. H., Nie, W., Yang, Y., Wu, C., Liu, W., Zhang, K., Zhang, Z., & Shi, J. (2020) · Theranostics · doi:10.7150/thno.50028 · Cited by 58
“For example, fibroblasts and macrophages are generally located near the blood vessels, while tumor cells are relative far away from the blood vessels [48-50].”
BackgroundWen, A. M., Lee, K. L., Cao, P., Pangilinan, K. D., Carpenter, B. L., Lam, P. M. W., Veliz, F. A., Ghiladi, R. A., Advíncula, R. C., & Steinmetz, N. F. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00075 · Cited by 58
Alaarg, A., Jordan, N. Y., Verhoef, J. J. F., Metselaar, J. M., Storm, G., & Kok, R. J. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s115995 · Cited by 60
“Macrophages are known to be the most efficient in uptake of nanoparticles among the different cell types and may act as a reservoir for nanotherapeutics.(13,22) Figure 3 shows that RAW264.”
Ouyang, C., Chen, L., Rees, T. W., Chen, Y., Liu, J., Ji, L., Long, J., & Chao, H. (2018) · Chemical Communications · doi:10.1039/c8cc02795a · Cited by 59
Mo, J., Wang, L., Huang, X., Lu, B., Zou, C., Wei, L. S., Chu, J., Eggers, P. K., Chen, S., Raston, C. L., et al. (2017) · Nanoscale · doi:10.1039/c7nr04473a · Cited by 57
Naumenko, V., Nikitin, A., Garanina, A., Melnikov, P., Vodopyanov, S., Kapitanova, K., Potashnikova, D., Vishnevskiy, D., Alieva, I., Ilyasov, A., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.01.011 · Cited by 56
Innate and adaptive immune responses toward nanomedicines
Viana, I. M. D. O., Roussel, S., Defrêne, J., Lima, E. M., Barabé, F., & Bertrand, N. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.022 · Cited by 63
“In cancer, systemically injected nanoparticles can preferentially distribute to solid tumors 87 where they can target cancer cells and macrophages alike 88 .”
Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors
Zhang, J., Wang, S., Zhang, D. D., He, X., Wang, X., Han, H., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1230893 · Cited by 79
Cancer Nanomedicine: Mechanisms, Obstacles and Strategies
Li, H., Jin, H., Wan, W., Wu, C., & Wei, L. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0007 · Cited by 53
Current status of nanoscale drug delivery systems for colorectal cancer liver metastasis
Hong, Y. K., & Rao, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108764 · Cited by 57
Simón‐Gracia, L., Scodeller, P., Fuentes, S. S., Gómez‐Vallejo, V., Ríos, X., Sebastián, E. S., Sidorenko, V., Silvio, D. D., Suck, M., Lorenzi, F. D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24588 · Cited by 53
“TAMs are an important therapeutic target, which play major roles in progression of solid tumors and can act as slow-release reservoir of drugs encapsulated in polymeric particles [49].”
Design principles of drug combinations for chemotherapy
Wu, D., Pusuluri, A., Vogus, D. R., Krishnan, V., Shields, C. W., Kim, J., Razmi, A. N., & Mitragotri, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.018 · Cited by 54
Polymeric materials for immune engineering: Molecular interaction to biomaterial design
Soni, S. S., & Rodell, C. B. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.01.016 · Cited by 54
Macpherson, A. M., Barry, S. C., Ricciardelli, C., & Oehler, M. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092967 · Cited by 56
“injected human ovarian cancer cells have shown that polymeric nanoparticles incorporating platinum accumulate in TAMs, then deliver their payload to neighbouring tumour cells and inflict DNA damage [361].”
BackgroundNanotechnology Tools Enabling Biological Discovery
Salvador-Morales, C., & Grodzinski, P. A. (2022) · ACS Nano · doi:10.1021/acsnano.1c10635 · Cited by 57
The expanding landscape of inflammatory cells affecting cancer therapy
Weissleder, R., & Pittet, M. J. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0524-y · Cited by 55
Self-citationEngineered anti-cancer nanomedicine for synergistic ferroptosis-immunotherapy
Zhang, X., Ge, H., Ma, Y., Song, L., Ma, Y., Tian, G., Wang, L., Meng, Q., & Sun, X. J. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.140688 · Cited by 52
Eskandari, A., Boodram, J. N., Cressey, P., Lü, C., Bruno, P. M., Hemann, M. T., & Suntharalingam, K. (2016) · Dalton Transactions · doi:10.1039/c6dt03811e · Cited by 50
Akhtar, N., Pradhan, N., Saha, A., Kumar, V., Biswas, O., Dey, S., Shah, M., Kumar, S., & Manna, D. (2019) · Chemical Communications · doi:10.1039/c9cc04518j · Cited by 50
Biomaterials-Mediated Engineering of the Immune System
Backlund, C. M., Jalili‐Firoozinezhad, S., Kim, B., & Irvine, D. J. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-040259 · Cited by 55
Unraveling the Role of the Tumor Extracellular Matrix to Inform Nanoparticle Design for Nanomedicine
Cassani, M., Fernandes, S., Pagliari, S., Cavalieri, F., Caruso, F., & Forte, G. (2025) · Advanced Science · doi:10.1002/advs.202409898 · Cited by 48
The evolution of nanomedicine: The rise of next-generation nanomaterials in cancer nanomedicine
Forgham, H., Chang, Y.-X., Wang, Y., Zhu, J., Liu, L., Biggs, H., Käkinen, A., Jiang, Y., You, X., Thurecht, K. J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx1576 · Cited by 54
“Moreover, NPs are held through collective interactions with tumor-associated macrophages (TAMs), which can act as NP reservoirs ( 32 ), and through cellular and extracellular matrix conditions that trap the NPs within the tumor microenvironment for longer retention ( 33 ).”
Elechalawar, C. K., Bhattacharya, D., Ahmed, M. T., Ravuri, H. G., Sridharan, K., Chaturbedy, P., Sinha, S. H., Jaggarapu, M. M. C. S., Narayan, K. P., Chakravarty, S., et al. (2019) · Nanoscale Advances · doi:10.1039/c9na00056a · Cited by 51
Membrane-Encapsulated Camouflaged Nanomedicines in Drug Delivery
Ghosh, S., Girigoswami, K., & Girigoswami, A. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0155 · Cited by 49
Cheng, J. Q., Zhang, Q., Fan, S., Zhang, A., Liu, B., Hong, Y., Guo, J., Cui, D., & Song, J. (2019) · Nanoscale · doi:10.1039/c9nr08261a · Cited by 49
Paun, R. A., Jurchuk, S., & Tabrizian, M. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10601 · Cited by 57
“28,29 This process, if validated, could address some of the diffusivity issues at the tumor-endothelial interface, as TAMs may infiltrate deeper into the tumor after nanoparticle sequestration and act as a slow-release drug depot, thus underlining the importance of considering non-cancerous cells…”
BackgroundLiang, C., Bai, X., Qi, C., Sun, Q., Han, X., Lan, T., Zhang, H., Zheng, X., Liang, R., Jiao, J., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120432 · Cited by 51
Biancacci, I., Sun, Q., Möckel, D., Gremse, F., Rosenhain, S., Kiessling, F., Bartneck, M., Hu, Q., Thewissen, M., Storm, G., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.046 · Cited by 46
Organ-on-chip systems as a model for nanomedicine
Stavrou, M., Phung, N. B., Grimm, J., & Andreou, C. (2023) · Nanoscale · doi:10.1039/d3nr01661g · Cited by 51
Xiao, W., Wang, J., Liang, M., & Song, M. (2022) · Theranostics · doi:10.7150/thno.78572 · Cited by 48
“proved that drug-loaded NPs are largely uptook by TAMs within tumor tissues while they aim to delivering drugs to the tumor cells [36-38], which significantly weakens the ability of NPs to eradicate tumor cells.”
BackgroundBhattacharyya, A., Dixit, A., Banerjee, S., Roy, B., Kumar, A., Karande, A. A., & Chakravarty, A. R. (2016) · RSC Advances · doi:10.1039/c6ra23118g · Cited by 45
Li, P., Gao, M., Hu, Z., Xu, T., Chen, J., Ma, Y., Li, S., & Gu, Y. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.128217 · Cited by 46
Zhang, T., Lin, F., Liu, W., Liu, Y., Guo, Z., Xiao, C., Zhuang, X., & Chen, X. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2021.101109 · Cited by 47
Nanomedicine Meets microRNA: Current Advances in RNA-Based Nanotherapies for Atherosclerosis
Gadde, S., & Rayner, K. J. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307481 · Cited by 44
Self-citationNanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy
Zhao, Y., Mamuti, M., An, H., Fang, X., Zhao, Y., & Wang, H. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120552 · Cited by 47
Picardi, M., Giordano, C., Pugliese, N., Esposito, M. G., Fatigati, M., Muriano, F., Rascato, M. G., Pepa, R. D., d’Ambrosio, A., Vigliar, E., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18348 · Cited by 46
Lugani, S., Halabi, E. A., Oh, J., Köhler, R. H., Peterson, H. M., Breakefield, X. O., Chiocca, E. A., Miller, M. A., Garris, C., & Weissleder, R. (2022) · Advanced Materials · doi:10.1002/adma.202208782 · Cited by 46
Self-citationLin, J., Li, D., Li, C., Zhuang, Z., Chu, C., Ostrikov, K., Thompson, E. W., Liu, G., & Wang, P. (2023) · Nanoscale · doi:10.1039/d3nr01735d · Cited by 46
Sulheim, E., Kim, J., van Wamel, A., Kim, E., Snipstad, S., Vidic, I., Grimstad, I. H., Widerøe, M., Torp, S. H., Lundgren, S., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.026 · Cited by 41
Macrophage-Encapsulated Bioorthogonal Nanozymes for Targeting Cancer Cells
Das, R., Hardie, J. M., Joshi, B. P., Zhang, X., Gupta, A., Luther, D. C., Fedeli, S., Farkas, M. E., & Rotello, V. M. (2022) · JACS Au · doi:10.1021/jacsau.2c00247 · Cited by 45
Nguyen, V. D., Han, J., Go, G., Zhen, J., Zheng, S., Le, V. H., Park, J.-O., & Park, S. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.09.076 · Cited by 43
Leveraging microenvironmental synthetic lethalities to treat cancer
Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143765 · Cited by 42
“The host defense peptide synthetic analog RP-182 binds to the CD206 receptor on tumor-promoting TAMs and activates RAC1/CDC42 signaling.”
BackgroundInfluentialContext-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors
Conway, J. R. W., Warren, S. C., & Timpson, P. (2017) · Methods · doi:10.1016/j.ymeth.2017.04.014 · Cited by 42
“741 Similarly, by co-opting the tumor-association of TAMs, has allowed their use as 742 slow-release depots for Pt-based pro-drugs [253].”
MethodDacoba, T. G., Anfray, C., Mainini, F., Allavena, P., Alonso, M. J., Andón, F. T., & Crecente‐Campo, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01412 · Cited by 43
“Once in the tumor, a preferential uptake of the nanosystems by macrophages could be anticipated due to their high phagocytic capacity, as already described for both, targeted and non-targeted nanosystems (15, 54, 55).”
BackgroundRecent Progress in Bio-Responsive Drug Delivery Systems for Tumor Therapy
Cong, X., Chen, J., & Xu, R. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.916952 · Cited by 42
Nanomaterial‐mediated platinum drug‐based combinatorial cancer therapy
Deng, Z., Wang, N., Ai, F., Wang, Z., & Zhu, G. (2020) · View · doi:10.1002/viw.20200030 · Cited by 42
Tan, T., Wang, Y., Wang, J., Wang, Z., Wang, H., Cao, H., Li, J., Li, Y., Zhang, Z., & Wang, S. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.05.006 · Cited by 40
Zhu, C., Shi, Y., & You, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01248 · Cited by 39
Metadata
- Authors
- Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., Kolishetti, N., Pittet, M., Lippard, S. J., Farokhzad, O. C., & Weissleder, R.
- Affiliations
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Weissleder, Ralph
- ORCID
- Venue
- Nature Communications
- Published
- 2015-10-27
- Volume
- 6
- Issue
- 1
- Pages
- 8692-8692
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4711745
- OpenAlex
- W1874889006
- Cited by
- 441
- References
- 70
- Citations by year
- 2026: 18 · 2025: 29 · 2024: 38 · 2023: 40 · 2022: 40 · 2021: 46 · 2020: 62 · 2019: 55 · 2018: 48 · 2017: 42 · 2016: 23
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- Deutsche Forschungsgemeinschaft (PF809/1-1, CA034992)
- National Institutes of Health (CA151884, U54-CA151884, CA034992, CA139980, PO1-CA139980)
- National Cancer Institute (CA-034992, CA139980, P50CA086355, R01CA164448, U54CA151884, P01CA139980, R37CA034992, CA151884, R01CA034992, P30CA014051, T32CA079443)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- tumour-associated macrophages, nanotherapeutics, pharmacodynamics, single-cell imaging, DNA damage response, slow drug release, TAM depletion, nanoparticle accumulation, cancer nanomedicine
- MeSH terms
- Animals, Antineoplastic Agents, Female, Humans, Macrophages, Mice, Inbred C57BL, Mice, Nude, Neoplasms, Platinum, Prodrugs, Drug Delivery Systems, Cell Line, Tumor, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.